i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Controversies about extended-spectrum and AmpC beta-lactamases.
-
Published Date:
2001 Mar-Apr
-
Source:Emerg Infect Dis. 7(2):333-336.
-
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:Many clinical laboratories have problems detecting extended-spectrum beta-lactamases (ESBLs) and plasmid-mediated AmpC beta-lactamases. Confusion exists about the importance of these resistance mechanisms, optimal test methods, and appropriate reporting conventions. Failure to detect these enzymes has contributed to their uncontrolled spread and sometimes to therapeutic failures. Although National Committee for Clinical Laboratory Standards recommendations exist for detecting ESBL- producing isolates of Escherichia coli and Klebsiella spp., no recommendations exist for detecting ESBLs in other organisms or for detecting plasmid-mediated AmpC beta-lactamases in any organisms. Clinical laboratories need to have adequate funding, equipment, and expertise to provide a rapid and clinically relevant antibiotic testing service in centers where these resistance mechanisms are encountered.
-
Subject:
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:
text/plain text/plain
No Related Documents.